论文部分内容阅读
目的 比较高危肾移植患者术后应用环孢素 A(CsA)和他克莫司(FK506)的疗效和安全性。方法 将58例高危肾移植患者随机分为CsA组(30例)和FK506组(28 例),观察肾移植后 1年内两组的急性排斥发生率和药物逆转率、药物毒副作用及感染发生情况。结果 FK506组和 CsA组的人/肾存活率分别为100%/100%和93.3%/86.7%;急性排斥反应发生率分别为14.3%和16.7%;抗排斥治疗的逆转率分别为100%和60%。FK506组药物毒副作用也较 CsA组小。结论 在高危肾移植患者的免疫抑制治疗中FK506应为首选。
Objective To compare the efficacy and safety of cyclosporin A (CsA) and tacrolimus (FK506) in high-risk renal transplant recipients. Methods 58 cases of high-risk renal transplantation were randomly divided into CsA group (n = 30) and FK506 group (n = 28). The incidence of acute rejection and drug reversal, drug toxicity and side effects and incidence of infection . Results The survival rates of human / kidney in FK506 group and CsA group were 100% / 100% and 93.3% / 86.7% respectively. The incidence of acute rejection was 14.3% and 16.7% respectively. The reversal rates of anti-rejection were 100% and 60%. FK506 group of drug side effects than CsA group smaller. Conclusion FK506 should be the first choice for immunosuppressive therapy in high-risk renal transplant recipients.